A systemic antifungal medicine reduced intestinal Candida and was associated with improved gut health in a small study of people with inflammatory bowel disease and oral thrush, Weill Cornell Medicine ...

Sept 2 (Reuters) - Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the ...

In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — ...

While Teva announced positive Phase II data, it has not yet confirmed Phase III plans.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) on Wednesday reported encouraging topline outcomes from an active Phase 2a clinical trial evaluating TEV ‘408, an experimental anti-interleukin-15 ...

Cases of giardiasis, an intestinal infection that causes diarrhea, bloating and gas, have reached their highest level in England since 2016, according to newly published data from the UK Health ...

It's a remarkable claim about the cause of multiple sclerosis - a devastating incurable illness that continues to baffle ...

The company's TEV-408 antibody met its primary endpoint in a 50-patient trial and reduced intestinal damage, inflammation and gastrointestinal symptoms. Teva is also advancing the treatment for ...

Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically ...

Abnormal epithelial cell-death signalling may persist during apparent IBD remission and could identify patients at greater ...

Denmark's Netcompany has been awarded a five-year contract from NHS England, worth more than £215 million, to build the ...

During a 12-hour anorectal screening drive in Pune, I screened 352 people and saw just how easily bowel symptoms are ...